Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141482 | 0.88 | AKT1 (0.38) | AKT1AKT2CNR1CNR2RET | |
| SCHEMBL1141689 | 0.85 | AKT1 (0.36) | AKT1AKT2CNR1CNR2PDE2A | |
| SCHEMBL1141426 | 0.80 | MAP2K4 (0.34) | ELANEUSP30GSK3BDYRK1A | |
| SCHEMBL11911449 | 0.79 | MAP2K4 (0.37) | RETELANEUSP30GSK3BDYRK1A | |
| SCHEMBL1141589 | 0.79 | GRM2 (0.40) | AKT1GSK3B | |
| SCHEMBL1141929 | 0.79 | ELANE (0.33) | ELANEUSP30 | |
| SCHEMBL1142108 | 0.79 | ABCB1 (0.34) | ELANE | |
| SCHEMBL4198509 | 0.78 | PTGER4 (0.41) | AKT1GSK3B | |
| SCHEMBL1142018 | 0.77 | MAP2K4 (0.32) | GSK3BDYRK1A | |
| SCHEMBL1141427 | 0.77 | POLB (0.36) | RETUSP30GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468729-B1 | Novel indazole derivative | UBE INDUSTRIES (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| CN-1863779-B | indazole derivatives | UBE INDUSTRIES | 2010-05-05 | — | — | CN | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | AKT1 28/4885AKT2 32/4885CNR1 943/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | AKT1 25/4885AKT2 33/4885CNR1 329/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | AKT1 28/4885AKT2 29/4885CNR1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.